Wayrilz (rilzabrutinib) — Medica

Initial criteria

• age ≥ 18 years
• EITHER platelet count < 30 × 10^9/L (<30,000/mcL) OR BOTH platelet count < 50 × 10^9/L (<50,000/mcL) AND increased risk of bleeding per prescriber
• EITHER tried at least one other therapy (e.g., systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, Promacta, Alvaiz, Nplate, Doptelet, Doptelet Sprinkle, Tavalisse, or rituximab) OR undergone splenectomy
• prescribed by or in consultation with a hematologist

Reauthorization criteria

• prescriber confirms beneficial clinical response (e.g., increased or maintained platelet counts and/or decreased frequency of bleeding episodes)
• patient remains at risk for bleeding complications

Approval duration

initial: 3 months; reauth: 1 year